DMT for Suicidality

5 papers and 0 clinical trials exploring dmt as a treatment for suicidality.

CompoundTryptamine

DMT

A powerful, short-acting tryptamine psychedelic found in many botanical sources, known for rapid onset and intense subjective experiences.

Full DMT profile
Indication700,000 deaths annually worldwide.

Suicidality

Suicidality encompasses a spectrum of suicidal thoughts and behaviours, significantly impacting individuals globally. Recent research into psychedelics, particularly ketamine and ayahuasca, shows promise in rapidly alleviating suicidal ideation associated with mental health disorders.

Full Suicidality profile

Academic Research

5 papers
Open Accessindividual

Safety, Pharmacokinetics, and Pharmacodynamics of a 6-h N,N-Dimethyltryptamine (DMT) Infusion in Healthy Volunteers: A Randomized, Double-Blind, Placebo-Controlled Trial

This randomized, double‑blind, placebo‑controlled study found that a 30‑s bolus followed by a 6‑hour intravenous DMT infusion (maximal exposures ≈35 ng/mL) was well tolerated in healthy volunteers with no serious adverse events and only mild, rapidly occurring psychedelic effects. Moderate interindividual pharmacokinetic variability was observed and the highest dose produced transient reductions in sustained attention, postural stability and occipital alpha power, providing a safety and PK/PD basis for future proof‑of‑mechanism studies in patient populations.

Published
Journal
Clinical and Translational Science
Authors
Bryan, C. S., de Kam, M. L., Jacobs, G. E., Otto, M. E., Stewart, N., Stillwell, C., van der Heijden, K. V., van Gerven, J. M. A., van Leuken, M. B., Zuiker, R. G. J. A.
Paywallmeta

Adverse Events in Studies of Classic Psychedelics: A Systematic Review and Meta-Analysis

This systematic review and meta‑analysis of 214 studies (3,504 participants with analysable adverse‑event data) found that high‑dose classic psychedelics were generally well tolerated in clinical/research settings, with serious adverse events occurring mainly in ~4% of participants who had preexisting neuropsychiatric disorders and no reports in contemporary trials of suicide, persistent psychotic disorder or hallucinogen‑persisting perception disorder. Common non‑serious adverse events (headache, anxiety, nausea, fatigue, dizziness) had similar prevalences for psilocybin and LSD, but substantial heterogeneity and limited systematic adverse‑event monitoring across studies highlight the need for improved pharmacovigilance.

Published
Journal
JAMA Psychiatry
Authors
Graziosi, M., Hinkle, J. T., Nayak, S., Yaden, D. B.
Open Accessindividual

5-MeO-DMT for post-traumatic stress disorder: a real-world longitudinal case study

This first longitudinal case study reports that a single inhaled dose of toad‑derived 5‑MeO‑DMT produced rapid, clinically significant and sustained reductions in PTSD symptoms, hopelessness and suicide risk in a 23‑year‑old woman, with the participant endorsing a complete mystical experience and no drug‑related serious adverse events. Improvements persisted to 12 months but were accompanied by acute nausea, overwhelming subjective effects and later night terrors, and the authors emphasise the single‑case design is non‑generalizable and requires controlled replication.

Published
Journal
Frontiers in Psychiatry
Authors
August, R. J., Averill, L. A., Barr, N., Barsuglia, J. P., Bass, L. C., Gaffrey, M. S., Jackson, L. K., Kaiyo, M., Khan, R., Ragnhildstveit, A., Seli, P.

Clinical Trials

0 trials

No clinical trials have been tagged with both DMT and Suicidality yet.

Trials are continuously being added as new studies are registered.

Explore further

Search all DMT papers Search all Suicidality trials Full DMT profile Full Suicidality profile
DMT for Suicidality — Research Papers & Clinical Trials | Blossom